Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Up 1,920.0% in January

Xenetic Biosciences Inc (NASDAQ:XBIO) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 10,100 shares, a growth of 1,920.0% from the December 31st total of 500 shares. Currently, 0.8% of the shares of the stock are sold short. Based on an average daily volume of 21,600 shares, the days-to-cover ratio is presently 0.5 days.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “neutral” rating on shares of Xenetic Biosciences in a research report on Thursday, December 5th.

Xenetic Biosciences Stock Down 3.4 %

Xenetic Biosciences stock opened at $4.01 on Wednesday. The business has a 50-day simple moving average of $4.17 and a 200 day simple moving average of $4.00. Xenetic Biosciences has a 52 week low of $2.78 and a 52 week high of $5.20. The stock has a market cap of $6.18 million, a price-to-earnings ratio of -1.51 and a beta of 2.22.

Xenetic Biosciences (NASDAQ:XBIO) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.14). Xenetic Biosciences had a negative return on equity of 49.51% and a negative net margin of 161.63%. The business had revenue of $0.61 million for the quarter, compared to analysts’ expectations of $0.75 million. On average, research analysts anticipate that Xenetic Biosciences will post -1.01 earnings per share for the current year.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.